[A05-19A] Cholinesterase inhibitors in Alzheimer's disease

Last updated 10.04.2007

Project no.:
A05-19A

Commission:
Commission awarded on 22.02.2005 by the Federal Joint Committee (G-BA).

Report type:
Report

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Head and nerves

10.09.2009

Alzheimer’s disease: only a few therapies provide proof of benefit to patients

Cholinesterase inhibitors and ginkgo may alleviate some symptoms – Non-drug approaches are insufficiently investigated – Marked increase in supporting...

Press release

10.04.2007

Cholinesterase inhibitors can slightly delay the deterioration of cognitive function

IQWiG publishes final report on a drug class for treatment of Alzheimer's disease

Press release

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

How effective are cholinesterase inhibitors?

Project no.	Title	Status
A09-05	Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine	Commission completed
A09-03	Update search on Report A05-19A (cholinesterase inhibitors in the treatment of Alzheimer's Disease) - Rapid report	Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form